Literature DB >> 20404137

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

David I Marks1, Tao Wang, Waleska S Pérez, Joseph H Antin, Edward Copelan, Robert Peter Gale, Biju George, Vikas Gupta, Joerg Halter, H Jean Khoury, Thomas R Klumpp, Hillard M Lazarus, Victor A Lewis, Philip McCarthy, David A Rizzieri, Mitchell Sabloff, Jeff Szer, Martin S Tallman, Daniel J Weisdorf.   

Abstract

We examined the efficacy of reduced-intensity conditioning (RIC) and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic leukemia (ALL) in first or second complete remission. RIC conditioning included busulfan 9 mg/kg or less (27), melphalan 150 mg/m(2) or less (23), low-dose total body irradiation (TBI; 36), and others (7). The RIC group was older (median 45 vs 28 years, P < .001) and more received peripheral blood grafts (73% vs 43%, P < .001) but had similar other prognostic factors. The RIC versus full-intensity conditioning groups had slightly, but not significantly, less acute grade II-IV graft-versus-host disease (39% vs 46%) and chronic graft-versus-host disease (34% vs 42%), yet similar transplantation-related mortality. RIC led to slightly more relapse (35% vs 26%, P = .08) yet similar age-adjusted survival (38% vs 43%, P = .39). Multivariate analysis showed that conditioning intensity did not affect transplantation-related mortality (P = .92) or relapse risk (P = .14). Multivariate analysis demonstrated significantly improved overall survival with: Karnofsky performance status more than 80, first complete remission, lower white blood count, well-matched unrelated or sibling donors, transplantation since 2001, age younger than 30 years, and conditioning with TBI, but no independent impact of conditioning intensity. RIC merits further investigation in prospective trials of adult ALL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404137      PMCID: PMC2913452          DOI: 10.1182/blood-2010-01-264077

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.

Authors:  G Massenkeil; M Nagy; S Neuburger; I Tamm; C Lutz; P le Coutre; O Rosen; K-D Wernecke; B Dörken; R Arnold
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

Review 3.  Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options.

Authors:  D I Marks; F Aversa; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2006-08-07       Impact factor: 5.483

4.  Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia.

Authors:  J R Passweg; P Tiberghien; J Y Cahn; M R Vowels; B M Camitta; R P Gale; R H Herzig; D Hoelzer; M M Horowitz; N Ifrah; J P Klein; D I Marks; N K Ramsay; P A Rowlings; D J Weisdorf; M J Zhang; A J Barrett
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

5.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

6.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

Authors:  P D Kottaridis; D W Milligan; R Chopra; R K Chakraverty; S Chakrabarti; S Robinson; K Peggs; S Verfuerth; R Pettengell; J C Marsh; S Schey; P Mahendra; G J Morgan; G Hale; H Waldmann; M C de Elvira; C D Williams; S Devereux; D C Linch; A H Goldstone; S Mackinnon
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

7.  Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients.

Authors:  T Hamaki; M Kami; Y Kanda; K Yuji; Y Inamoto; Y Kishi; K Nakai; I Nakayama; N Murashige; Y Abe; Y Ueda; M Hino; T Inoue; H Ago; M Hidaka; T Hayashi; T Yamane; N Uoshima; S Miyakoshi; S Taniguchi
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

8.  A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.

Authors:  David I Marks; Stephen J Forman; Karl G Blume; Waleska S Pérez; Daniel J Weisdorf; Armand Keating; Robert Peter Gale; Mitchell S Cairo; Edward A Copelan; John T Horan; Hillard M Lazarus; Mark R Litzow; Philip L McCarthy; Kirk R Schultz; David D Smith; Michael E Trigg; Mei-Jie Zhang; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2006-04       Impact factor: 5.742

9.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

10.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

Authors:  K M Sullivan; P L Weiden; R Storb; R P Witherspoon; A Fefer; L Fisher; C D Buckner; C Anasetti; F R Appelbaum; C Badger
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

View more
  71 in total

1.  Redefining transplant in acute leukemia.

Authors:  Rob Sellar; Anthony H Goldstone; Hillard M Lazarus
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Saurabh Chhabra; Kwang Woo Ahn; Zhen-Huan Hu; Sandeep Jain; Amer Assal; Jan Cerny; Edward A Copelan; Andrew Daly; Zachariah DeFilipp; Shahinaz M Gadalla; Robert Peter Gale; Siddhartha Ganguly; Betty K Hamilton; Gerhard Carl Hildebrandt; Jack W Hsu; Yoshihiro Inamoto; Abraham S Kanate; H Jean Khoury; Hillard M Lazarus; Mark R Litzow; Sunita Nathan; Richard F Olsson; Attaphol Pawarode; Olle Ringden; Jacob M Rowe; Ayman Saad; Bipin N Savani; Harry C Schouten; Sachiko Seo; Nirav N Shah; Melhem Solh; Robert K Stuart; Celalettin Ustun; Ann E Woolfrey; Jean A Yared; Edwin P Alyea; Matt E Kalaycio; Uday Popat; Ronald M Sobecks; Wael Saber
Journal:  Blood Adv       Date:  2018-11-13

3.  Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006.

Authors:  Kristine Doney; Ted A Gooley; H Joachim Deeg; Mary E D Flowers; Rainer Storb; Frederick R Appelbaum
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-21       Impact factor: 5.742

4.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

5.  Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

Authors:  G Kunter; J B Perkins; J Pidala; T Nishihori; M A Kharfan-Dabaja; T Field; H Fernandez; L Perez; F Locke; E Ayala; M Tomblyn; J L Ochoa-Bayona; B Betts; M Nieder; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2013-09-02       Impact factor: 5.483

6.  Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Authors:  Tara M Robinson; Ephraim J Fuchs; Mei-Jie Zhang; Andrew St Martin; Myriam Labopin; Daniel A Keesler; Didier Blaise; Asad Bashey; Jean-Henri Bourhis; Fabio Ciceri; Stefan O Ciurea; Steven M Devine; Mohamad Mohty; Shannon R McCurdy; Noel Milpied; Ian K McNiece; Vanderson Rocha; Rizwan Romee; Gerard Socie; Ibrahim Yakoub-Agha; Robert J Soiffer; Mary Eapen; Arnon Nagler
Journal:  Blood Adv       Date:  2018-06-12

7.  Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.

Authors:  Patrice Chevallier; Myriam Labopin; Gérard Socié; Reza Tabrizi; Sabine Furst; Bruno Lioure; Thierry Guillaume; Jacques Delaunay; Régis Peffault de La Tour; Stéphane Vigouroux; Jean El-Cheikh; Didier Blaise; Mauricette Michallet; Karin Bilger; Noel Milpied; Philippe Moreau; Mohamad Mohty
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

8.  Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

Review 9.  Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Authors:  Katharine A Hodby; David I Marks
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

Review 10.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.